Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
liposomal doxorubicin + cisplatin
- Development stage
- Unknown
- Lead developer
- Janssen Pharmaceutical
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Intravenous
01
Overview
Liposomal doxorubicin + cisplatin is a combination chemotherapy regimen consisting of pegylated liposomal doxorubicin (PLD), a liposome-encapsulated form of doxorubicin with prolonged circulation time, and cisplatin, a platinum-based DNA cross-linking agent. PLD works by inhibiting topoisomerase II and generating free radicals that damage DNA, delivered in liposomal form to enhance tumor targeting and reduce cardiotoxicity. Cisplatin forms DNA crosslinks, disrupting DNA synthesis and inducing apoptosis. This combination is investigated or used for cancers such as platinum-sensitive ovarian cancer and malignant pleural mesothelioma, with phase II evidence showing promising antitumor activity and manageable toxicity.
- Brand names
- Doxil + cisplatinLipodox + cisplatin
- Other names
- pegylated liposomal doxorubicin + cisplatinLD + cisplatinPLD + cisplatin
02
Targets
DNA
Beyond the preview
Go deeper on liposomal doxorubicin + cisplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on liposomal doxorubicin + cisplatin.